TEST:

4D Lifetest™ Lung Dx

"In a significant financial milestone, Xlife Sciences AG invests CHF 23.3 million in 4D Lifetec AG, acquiring a 20% stake in the company. With the agreement signed today, Xlife Sciences is not only bringing in a direct cash investment, but also an AI software developed specifically for 4D Lifetec, which will massively expand the functionality of the 4D Lifetest™ in the field of digital health. The strategic investment marks a significant turning point in the healthcare industry as it combines financial strength with cutting-edge technology to revolutionize early cancer detection."

"Swiss firm 4D Lifetec...has forged a partnership with the Molecular Diagnostics Group to produce and automate 4D Lifetec's cancer assays and develop the tests for high-throughput screening...The agreement covers 4D Lifetec's 4D Lifetest series of early cancer assays, including the 4D Lifetest Lung Dx the firm launched in Europe this year for detection of early-stage lung cancer and its CE IVD-marked 4D Lifetest assays for breast, prostate, and colon cancers..."